Pulmonary Arterial Hypertension Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Collaboration, and Other Developments

The pulmonary arterial hypertension therapeutics pipeline is expected to increase in over next few years due to increasing prevalence of pulmonary arterial hypertension. Pulmonary arterial hypertension causes difficulty in blood supply to the lungs due to stiffness, tightening or blockage of a pulmonary artery. Some of the drivers for the growth of pulmonary arterial hypertension therapeutics pipeline include increasing incidence of vascular disease, change in lifestyle, sedentary lifestyle, lack of physical activity, increase in levels of blood pressure in people and obesity. As estimated by the current scenario, 15-50 cases per million have been found across the world. The prevalence of pulmonary arterial hypertension in HIV patients is 0.5%, while that in systemic sclerosis patients is 7% to 12% and is in the range of 2-3.75% in sickle cell disease patients.

Explore Report at: www.psmarketresearch.com/market-analysis/pulmonary-arterial-hypertension-therapeutics-pipeline-analysis

Pulmonary arterial hypertension is characterized by abnormally high blood pressure in pulmonary artery and other blood vessels that carries blood from the heart to the lungs, which causes shortness of breath during routine activity, chest pains, tiredness and racing heartbeat. Pulmonary arterial hypertension occurs due to inflammation in the pulmonary arteries. It also occurs because of tightening of arterial walls, stiffness and blood clot formation in the arteries, due to which it becomes difficult to push blood through the pulmonary arteries into the lungs.

Request for Table of Content at: www.psmarketresearch.com/market-analysis/pulmonary-arterial-hypertension-therapeutics-pipeline-analysis/toc-sample

Many institutes or associations and companies are collaborating for developing therapeutics for pulmonary arterial hypertension. Glaxosmithkline Plc and Myogen, Inc. is collaborating for development and commercialization of selective endothelin receptor antagonist, which is currently in Phase III. United therapeutics corporation collaborated with Ascendis Pharma A/S for development and commercialization of self-injectable Treptostinil for the treatment of pulmonary hypertension.

Browse Other Related Report at: www.psmarketresearch.com/industry-report/pharmaceuticals

Some of the key players having a pipeline of arterial hypertension therapeutics include Merck Sharp & Dohme Corp., Bayer AG, Pfizer Inc., Eli Lilly and Company, Eiger BioPharmaceuticals, Inc. Arena Pharmaceuticals, United Therapeutics Corporation, Reata Pharmaceuticals, Inc., GlaxoSmithKline Plc.

About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact:
Abhishek
Executive – Client Partner
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +1-888-778-7886 (USA/Canada)
Email: enquiry@psmarketresearch.com
Web: www.psmarketresearch.com

347, 5th Ave. #1402
New York City, NY - 10016

This release was published on openPR.